Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agustin Zavala

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Computer-Aided Molecular Design|September 3, 2017
Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculationsEdithe Selwa, Eddy Elisée, Agustin Zavala, et al.
ACS Infectious Diseases|February 22, 2019
Genetic, Biochemical, and Structural Characterization of CMY-136 β-Lactamase, a Peculiar CMY-2 VariantAgustin Zavala, Pascal Retailleau, Eddy Elisée, et al.
ACS Infectious Diseases|March 12, 2020
Substrate Specificity of OXA-48 after β5-β6 Loop ReplacementLaura Dabos, Agustin Zavala, Rémy A Bonnin, et al.
ACS Synthetic Biology|September 27, 2017
A Modular Receptor Platform To Expand the Sensing Repertoire of BacteriaHung-Ju Chang, Pauline Mayonove, Agustin Zavala, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|July 20, 2017
Beta-lactamase database (BLDB) - structure and functionThierry Naas, Saoussen Oueslati, Rémy A Bonnin, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2018
Genetic and Biochemical Characterization of OXA-519, a Novel OXA-48-Like β-LactamaseLaura Dabos, Pierre Bogaerts, Remy A Bonnin, et al.
The Journal of Antimicrobial Chemotherapy|May 26, 2019
Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activitySaoussen Oueslati, Bogdan I Iorga, Linda Tlili, et al.
Nature Communications|March 19, 2024
Cryo-EM structures of type IV pili complexed with nanobodies reveal immune escape mechanismsDavid Fernandez-Martinez, Youxin Kong, Sylvie Goussard, et al.
Antimicrobial Agents and Chemotherapy|January 17, 2023
Structural and Biochemical Features of OXA-517: a Carbapenem and Expanded-Spectrum Cephalosporin Hydrolyzing OXA-48 VariantLaura Dabos, Joanna E Raczynska, Pierre Bogaerts, et al.
European Journal of Medicinal Chemistry|April 16, 2021
Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D)Eugénie Romero, Saoussen Oueslati, Mohamed Benchekroun, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Computer-Aided Molecular Design|September 3, 2017
Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculationsEdithe Selwa, Eddy Elisée, Agustin Zavala, et al.
ACS Infectious Diseases|February 22, 2019
Genetic, Biochemical, and Structural Characterization of CMY-136 β-Lactamase, a Peculiar CMY-2 VariantAgustin Zavala, Pascal Retailleau, Eddy Elisée, et al.
ACS Infectious Diseases|March 12, 2020
Substrate Specificity of OXA-48 after β5-β6 Loop ReplacementLaura Dabos, Agustin Zavala, Rémy A Bonnin, et al.
ACS Synthetic Biology|September 27, 2017
A Modular Receptor Platform To Expand the Sensing Repertoire of BacteriaHung-Ju Chang, Pauline Mayonove, Agustin Zavala, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|July 20, 2017
Beta-lactamase database (BLDB) - structure and functionThierry Naas, Saoussen Oueslati, Rémy A Bonnin, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2018
Genetic and Biochemical Characterization of OXA-519, a Novel OXA-48-Like β-LactamaseLaura Dabos, Pierre Bogaerts, Remy A Bonnin, et al.
The Journal of Antimicrobial Chemotherapy|May 26, 2019
Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activitySaoussen Oueslati, Bogdan I Iorga, Linda Tlili, et al.
Nature Communications|March 19, 2024
Cryo-EM structures of type IV pili complexed with nanobodies reveal immune escape mechanismsDavid Fernandez-Martinez, Youxin Kong, Sylvie Goussard, et al.
Antimicrobial Agents and Chemotherapy|January 17, 2023
Structural and Biochemical Features of OXA-517: a Carbapenem and Expanded-Spectrum Cephalosporin Hydrolyzing OXA-48 VariantLaura Dabos, Joanna E Raczynska, Pierre Bogaerts, et al.
European Journal of Medicinal Chemistry|April 16, 2021
Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D)Eugénie Romero, Saoussen Oueslati, Mohamed Benchekroun, et al.
Pageof 1